Compare GDYN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDYN | ODTX |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2018 | 2025 |
| Metric | GDYN | ODTX |
|---|---|---|
| Price | $13.22 | $19.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $13.00 | ★ $34.67 |
| AVG Volume (30 Days) | ★ 1.9M | 282.2K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $6.93 | N/A |
| Revenue Next Year | $9.86 | N/A |
| P/E Ratio | $148.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.11 | $15.10 |
| 52 Week High | $14.14 | $29.05 |
| Indicator | GDYN | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.97 | 45.36 |
| Support Level | $5.57 | $15.73 |
| Resistance Level | $14.02 | $19.60 |
| Average True Range (ATR) | 0.81 | 1.79 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 83.79 | 18.74 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.